Dejan Juric, MD, Massachusetts General Hospital
Advertisement
Articles by Dejan Juric, MD, Massachusetts General Hospital
Advertisement
Latest Updated Articles
PI3KCA Inhibition: Managing AEs in HR+ mBCPublished: July 21st 2021 | Updated:
Early Stage HR+ Breast Cancer: Optimizing Multigene AssaysPublished: August 4th 2021 | Updated:
Using Genomic Assays for Early Stage HR+ Breast CancerPublished: July 28th 2021 | Updated:
ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical PracticePublished: August 11th 2021 | Updated:
Emerging Agents for the Management of HR+ mBCPublished: July 28th 2021 | Updated:
Using CDK4/6 Inhibitors After HR+ mBC Disease ProgressionPublished: July 21st 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5